Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Hypertension Diagnostics stock

HDII
US44914V1044
657841

Price

0.00
Today +/-
+0
Today %
+0 %
P

Hypertension Diagnostics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Hypertension Diagnostics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Hypertension Diagnostics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Hypertension Diagnostics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Hypertension Diagnostics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Hypertension Diagnostics Stock Price History

DateHypertension Diagnostics Price
11/13/20240.00 undefined
10/29/20240.00 undefined

Hypertension Diagnostics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hypertension Diagnostics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hypertension Diagnostics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hypertension Diagnostics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hypertension Diagnostics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hypertension Diagnostics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hypertension Diagnostics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hypertension Diagnostics’s growth potential.

Hypertension Diagnostics Revenue, EBIT and net profit per share

DateHypertension Diagnostics RevenueHypertension Diagnostics EBITHypertension Diagnostics Net Income
20183.79 M undefined710 undefined-125,390 undefined
20173.68 M undefined-244,990 undefined-368,610 undefined
20163.57 M undefined-500,510 undefined-621,710 undefined
20123.16 M undefined-1.36 M undefined-1.26 M undefined
20110 undefined-365,640 undefined406,310 undefined
20101.38 M undefined-999,170 undefined-989,760 undefined
2009500,000 undefined-260,000 undefined-250,000 undefined
2008550,000 undefined-750,000 undefined-700,000 undefined
20071.88 M undefined-570,000 undefined-500,000 undefined
20061.79 M undefined-1.32 M undefined-1.27 M undefined
20051.18 M undefined-1.49 M undefined-1.46 M undefined
20041.07 M undefined-1.82 M undefined-1.84 M undefined
2003780,000 undefined-3.58 M undefined-3.8 M undefined
2002550,000 undefined-5.99 M undefined-6.37 M undefined
20012.05 M undefined-2.46 M undefined-2.26 M undefined
2000420,000 undefined-3.64 M undefined-3.33 M undefined
1999380,000 undefined-2.63 M undefined-2.21 M undefined
19980 undefined-1.21 M undefined-1.14 M undefined
19970 undefined-950,000 undefined-870,000 undefined
19960 undefined-770,000 undefined-720,000 undefined

Hypertension Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201620172018
00000200111100103333
--------------------
-----50.00--100.00100.00100.00100.00--100.00-33.3333.3333.3333.33
000001,0000001,0001,0001,000001,00000000
00-1-2-3-2-6-3-1-1-100000-1000
---100.0050.00-33.33200.00-50.00-66.67-----------
1.251.962.224.975.135.375.968.3821.7528.5135.2239.7939.6940.7241.2842.6546.8252.3952.3952.39
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The Hypertension Diagnostics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hypertension Diagnostics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19961997199819992000200120022003200420052006200720082009201020112012201620172018
                                       
1.981.21.247.694.023.891.820.091.381.531.721.381.080.71.050.750.080.190.290.09
000180705028012021090180290304038.070149.16173.83180.59187.6
001050001202010000000125148.72181.37190.61200.33
000.040.381.31.31.390.330.230.320.340.290.290.280.4400.170.180.190.19
00101010109040602020201004.99383.7631.338.0539.9541.95
1.981.21.38.315.45.253.70.61.891.962.261.981.411.021.541.260.580.770.880.71
10012038036055059052036023080401001.340678.33576.83545.53509.53
00000000000000000000
00000000000000000000
10103020201000000000000000
00000000000000000000
0015010101010401010101010106.5323.3751.0458.4560.4962.6
2010300410390570600560370240905020107.8723.37729.37635.28606.02572.13
21.211.68.725.795.824.31.162.262.22.352.031.431.031.551.291.311.41.491.28
                                       
20203050506070100270340410410410420426.27439.37530530.03530.03530.03
3.223.324.6714.0814.2116.5320.0421.4324.5925.9727.4127.527.627.6827.852828.4628.4628.4628.46
-1.26-2.13-3.28-5.49-8.82-11.24-17.61-21.41-23.25-24.71-25.98-26.48-27.19-27.44-28.42-28.02-29.28-33.25-33.62-33.74
000-160-80-10000000000000100
00000000000000000000
1.981.211.428.485.365.342.50.121.611.61.841.430.820.66-0.150.42-0.29-4.26-4.62-4.75
201019011017024015010090906020202014.090170.83400.19422.14445.64
0000.110.250.240.280.30.550.480.420.520.530.050.2200.281.061.270.9
0000000.070.1500.010.010.050.030.271.390.860.17000
00000000000000000000
0000001.270.48000000000.04000
0.020.010.190.220.420.481.771.030.640.580.490.590.580.341.620.870.651.461.691.34
00000000000000000.684.24.424.69
00000000000000000000
00000040010202010303070.550262.5000
0000000.0400.010.020.020.010.030.030.0700.944.24.424.69
0.020.010.190.220.420.481.811.030.650.60.510.60.610.371.690.871.595.666.116.03
21.221.618.75.785.824.311.152.262.22.352.031.431.031.551.291.311.41.491.28
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hypertension Diagnostics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hypertension Diagnostics's financial health and stability.

Assets

Hypertension Diagnostics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hypertension Diagnostics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hypertension Diagnostics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hypertension Diagnostics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19961997199819992000200120022003200420052006200720082009201020112012201620172018
00-1-2-3-2-6-3-1-1-100000-1000
00000000000000000000
00000000000000000000
00000001,000000000000000
00000020000000100000
00000000000000000000
00000000000000000000
00-1-2-3-2-4-1-10000000-1000
00000000000000000000
00000000000000000000
00000000000000000000
00000000000000000000
00000020000000000000
20190200210000000000
20190220210000000000
--------------------
00000000000000000000
1006-30-2-1100000000000
-0.41-0.78-1.27-2.76-3.8-2.24-4.11-1.79-1.48-0.88-0.78-0.31-0.3-0.380.28-0.2-1.86-0.39-0.09-0.39
00000000000000000000

Hypertension Diagnostics stock margins

The Hypertension Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hypertension Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hypertension Diagnostics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hypertension Diagnostics's sales revenue. A higher gross margin percentage indicates that the Hypertension Diagnostics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hypertension Diagnostics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hypertension Diagnostics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hypertension Diagnostics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hypertension Diagnostics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hypertension Diagnostics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hypertension Diagnostics Margin History

Hypertension Diagnostics Gross marginHypertension Diagnostics Profit marginHypertension Diagnostics EBIT marginHypertension Diagnostics Profit margin
201825.17 %0.02 %-3.31 %
201720.46 %-6.66 %-10.02 %
201615.45 %-14.03 %-17.43 %
2012-3.54 %-43.08 %-40 %
201125.17 %0 %0 %
2010101.44 %-72.21 %-71.53 %
200976 %-52 %-50 %
200892.73 %-136.36 %-127.27 %
200796.28 %-30.32 %-26.6 %
200694.97 %-73.74 %-70.95 %
200584.75 %-126.27 %-123.73 %
200484.11 %-170.09 %-171.96 %
2003-26.92 %-458.97 %-487.18 %
200281.82 %-1,089.09 %-1,158.18 %
200177.07 %-120 %-110.24 %
200071.43 %-866.67 %-792.86 %
199963.16 %-692.11 %-581.58 %
199825.17 %0 %0 %
199725.17 %0 %0 %
199625.17 %0 %0 %

Hypertension Diagnostics Stock Sales Revenue, EBIT, Earnings per Share

The Hypertension Diagnostics earnings per share therefore indicates how much revenue Hypertension Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hypertension Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hypertension Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hypertension Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hypertension Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hypertension Diagnostics Revenue, EBIT and net profit per share

DateHypertension Diagnostics Sales per ShareHypertension Diagnostics EBIT per shareHypertension Diagnostics Earnings per Share
20180.07 undefined0 undefined-0 undefined
20170.07 undefined-0 undefined-0.01 undefined
20160.07 undefined-0.01 undefined-0.01 undefined
20120.07 undefined-0.03 undefined-0.03 undefined
20110 undefined-0.01 undefined0.01 undefined
20100.03 undefined-0.02 undefined-0.02 undefined
20090.01 undefined-0.01 undefined-0.01 undefined
20080.01 undefined-0.02 undefined-0.02 undefined
20070.05 undefined-0.01 undefined-0.01 undefined
20060.05 undefined-0.04 undefined-0.04 undefined
20050.04 undefined-0.05 undefined-0.05 undefined
20040.05 undefined-0.08 undefined-0.08 undefined
20030.09 undefined-0.43 undefined-0.45 undefined
20020.09 undefined-1.01 undefined-1.07 undefined
20010.38 undefined-0.46 undefined-0.42 undefined
20000.08 undefined-0.71 undefined-0.65 undefined
19990.08 undefined-0.53 undefined-0.44 undefined
19980 undefined-0.55 undefined-0.51 undefined
19970 undefined-0.48 undefined-0.44 undefined
19960 undefined-0.62 undefined-0.58 undefined

Hypertension Diagnostics business model

Hypertension Diagnostics Inc. is a biotechnology company specializing in the development and production of medical devices for the diagnosis of arterial hypertension. The company was founded in 1999 by a team of experienced engineers and scientists with the goal of providing the healthcare sector with new effective solutions for the widespread problem of high blood pressure. Hypertension Diagnostics' business model is based on the development and marketing of medical devices for blood pressure measurement, specifically designed for clinical and ambulatory use in medical practices, clinics, or at home. The company's technology aims to provide better and more reliable options for early detection and treatment of hypertension, ultimately contributing to a reduction in associated risks such as cardiovascular diseases, kidney failure, and strokes. Hypertension Diagnostics offers various divisions in their business. These include product development, sales and marketing team, as well as customer support team. The company also operates a research and development department focused on clinical studies and continuous improvement of existing products. Hypertension Diagnostics' products include blood pressure measurement devices with various features, such as portable devices for home use, certified blood pressure monitors for ambulatory and clinical diagnostics, as well as blood pressure monitors for operation under adverse conditions. This also includes wireless monitoring systems that allow doctors to monitor the blood pressure behavior of patients over an extended period without the patient having to stay in the hospital. The company has also developed a range of software applications that can access and analyze patient data. The goal of Hypertension Diagnostics is to provide the healthcare sector with innovative and high-quality blood pressure measurement devices that enable better early detection and treatment of hypertension for physicians, clinics, and patients. The company is committed to continuously developing and improving its technology to better meet the needs of its customers and patients. Overall, Hypertension Diagnostics is a company focused on improving healthcare through innovative medical devices for the diagnosis of high blood pressure. The company has a strong track record in the development and marketing of blood pressure measurement devices and has earned an excellent reputation in the industry. Thanks to its strong R&D team and commitment to product quality, Hypertension Diagnostics is expected to continue playing a key role in providing advanced medical solutions to reduce the rate of hypertension-related diseases in the future. Hypertension Diagnostics is one of the most popular companies on Eulerpool.com.

Hypertension Diagnostics SWOT Analysis

Strengths

  • Established reputation in the medical industry.
  • Strong patent portfolio for innovative diagnostic technologies.
  • Robust distribution network with wide market reach.

Weaknesses

  • Reliant on a limited range of diagnostic products.
  • Vulnerability to fluctuations in regulatory frameworks.
  • Lack of diversification in revenue sources.

Opportunities

  • Growing global demand for hypertension diagnostic solutions.
  • Entry into emerging markets with underserved medical needs.
  • Strategic partnerships and collaborations to expand product range.

Threats

  • Intense competition from established and emerging competitors.
  • Potential disruptive technologies affecting the diagnostic industry.
  • Stringent regulatory requirements and compliance challenges.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Hypertension Diagnostics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Hypertension Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Hypertension Diagnostics shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hypertension Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hypertension Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hypertension Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hypertension Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Hypertension Diagnostics.

Hypertension Diagnostics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2001-0.23 -0.2  (14.75 %)2001 Q2
1

Hypertension Diagnostics shareholders

%
Name
Stocks
Change
Date
0 % Boston Family Office, LLC0-36,0009/30/2020
1

Hypertension Diagnostics Executives and Management Board

Kenneth Brimmer(57)
Hypertension Diagnostics Chief Executive Officer, Chief Financial Officer, Director (since 1995)
Compensation 287,697
Larry Leitner(59)
Hypertension Diagnostics Independent Director
1

Most common questions regarding Hypertension Diagnostics

What values and corporate philosophy does Hypertension Diagnostics represent?

Hypertension Diagnostics Inc is a reputable company in the field of healthcare and diagnostics. The company's values and corporate philosophy revolve around commitment to high-quality patient care and innovation. Hypertension Diagnostics Inc believes in delivering accurate and reliable diagnostics solutions to effectively manage and treat hypertension. With a strong focus on research and development, the company aims to continuously improve and provide advanced medical technologies to professionals and patients worldwide. Hypertension Diagnostics Inc is dedicated to improving the quality of life for individuals with hypertension through their cutting-edge products and services.

In which countries and regions is Hypertension Diagnostics primarily present?

Hypertension Diagnostics Inc primarily operates in the United States.

What significant milestones has the company Hypertension Diagnostics achieved?

Hypertension Diagnostics Inc has achieved several significant milestones. The company successfully developed and introduced innovative diagnostic methods for high blood pressure detection, revolutionizing the healthcare industry. Hypertension Diagnostics Inc also received various accolades and recognition for its cutting-edge research and development. Additionally, the company established successful partnerships with renowned medical institutions and pharmaceutical companies, further bolstering its reputation and market presence. These achievements demonstrate Hypertension Diagnostics Inc's commitment to advancing hypertension diagnostics and improving patient care in the field of cardiovascular health.

What is the history and background of the company Hypertension Diagnostics?

Hypertension Diagnostics Inc is a company specializing in the development and manufacturing of diagnostic devices to monitor hypertension. Founded in [year], the company has since established itself as a leader in the industry, providing innovative solutions to healthcare professionals worldwide. With a focus on accuracy, reliability, and patient comfort, Hypertension Diagnostics Inc has become a trusted name in the field of hypertension monitoring. Through continuous research and technological advancements, the company strives to improve the diagnosis and management of hypertension, ultimately contributing to better patient outcomes.

Who are the main competitors of Hypertension Diagnostics in the market?

The main competitors of Hypertension Diagnostics Inc in the market include companies like Medtronic, Omron Healthcare, and Philips Healthcare.

In which industries is Hypertension Diagnostics primarily active?

Hypertension Diagnostics Inc is primarily active in the healthcare and medical device industries.

What is the business model of Hypertension Diagnostics?

The business model of Hypertension Diagnostics Inc revolves around providing innovative solutions for diagnosing and monitoring hypertension, a prevalent medical condition characterized by high blood pressure. Hypertension Diagnostics Inc develops and manufactures advanced medical devices and technologies that aid healthcare professionals in accurately assessing and managing patients' blood pressure levels. With a focus on product development and clinical research, the company aims to improve patient outcomes by offering reliable and efficient tools for hypertension diagnosis. By constantly advancing their technologies, Hypertension Diagnostics Inc strives to contribute to the overall improvement of healthcare in the field of hypertension management.

What is the P/E ratio of Hypertension Diagnostics 2024?

The P/E ratio cannot be calculated for Hypertension Diagnostics at the moment.

What is the P/S ratio of Hypertension Diagnostics 2024?

The P/S cannot be calculated for Hypertension Diagnostics currently.

What is the Quality Investing of Hypertension Diagnostics?

The Quality Investing for Hypertension Diagnostics is 3/10.

What is the revenue of Hypertension Diagnostics 2024?

The revenue cannot currently be calculated for Hypertension Diagnostics.

How high is the profit of Hypertension Diagnostics 2024?

The profit cannot currently be calculated for Hypertension Diagnostics.

What is the business model of Hypertension Diagnostics

Hypertension Diagnostics Inc. is a company that specializes in the development, production, and distribution of medical devices and diagnostic equipment for the study of hypertension and cardiovascular diseases. With over 30 years of experience in this field, Hypertension Diagnostics Inc. is an established provider of high-quality products for research institutions and clinical facilities worldwide.

What is the Hypertension Diagnostics dividend?

Hypertension Diagnostics pays a dividend of 0 USD distributed over payouts per year.

How often does Hypertension Diagnostics pay dividends?

The dividend cannot currently be calculated for Hypertension Diagnostics or the company does not pay out a dividend.

What is the Hypertension Diagnostics ISIN?

The ISIN of Hypertension Diagnostics is US44914V1044.

What is the Hypertension Diagnostics WKN?

The WKN of Hypertension Diagnostics is 657841.

What is the Hypertension Diagnostics ticker?

The ticker of Hypertension Diagnostics is HDII.

How much dividend does Hypertension Diagnostics pay?

Over the past 12 months, Hypertension Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hypertension Diagnostics is expected to pay a dividend of 0 USD.

What is the dividend yield of Hypertension Diagnostics?

The current dividend yield of Hypertension Diagnostics is .

When does Hypertension Diagnostics pay dividends?

Hypertension Diagnostics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hypertension Diagnostics?

Hypertension Diagnostics paid dividends every year for the past 0 years.

What is the dividend of Hypertension Diagnostics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hypertension Diagnostics located?

Hypertension Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hypertension Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hypertension Diagnostics from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Hypertension Diagnostics pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Hypertension Diagnostics in the year 2023?

In the year 2023, Hypertension Diagnostics distributed 0 USD as dividends.

In which currency does Hypertension Diagnostics pay out the dividend?

The dividends of Hypertension Diagnostics are distributed in USD.

All fundamentals about Hypertension Diagnostics

Our stock analysis for Hypertension Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hypertension Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.